Children require the omega-3 fatty acids called EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) for healthy physical and mental development. EPA and DHA can be made in the body from omega-3 bearing vegetable oils, or supplied in ocean fish oils. However, over the last 20 or so years social and family standards for childhood nutrition have permitted significant percents of daily calories to come ‘foods’ that do not support the robust in-body production of EPA and DHA needed for optimal physical and mental development.
Many children today suffer from health conditions related to EPA and DHA deficits. Examples include attention deficit/hyperactivity disorder (ADD/ADHD), aggressive/hostility behavior, and bronchial asthma. Also, adequacy in EPA and DHA facilitates the full potential of visual and cognitive development and reduces risk for childhood Type 2 diabetes. Supplementation with EPA and DHA over 3 to 12 months may improve the life quality of children with cystic fibrosis, and lessen the hyperactivity and stereotype seen in autism.
This product assists parents in the difficult task of ensuring that their children receive adequacy in EPA and DHA. Each softgel supplies 100 mg of EPA and 50 mg DHA, with natural orange flavoring for chewing when required.
For children too small to chew, squeeze the softgel contents into food. This ocean fish oil is ultra purified by molecular distillation, a state of the art method for removing toxic metals and organic substances. Please see label for recommended amounts.
References:
Amminger, G.P., et al, Omega-3 fatty acids supplementation in children with autism: A double-blind, randomized, placebo-controlled pilot trial, Biol Psychiatry, Aug 22; 2006; Epub ahead of print. Refer to PubMed ID No. 16920077
Antalis, C.J., et al, Omega-3 fatty acids in attention-deficit/hyperactivity disorder, Prostaglandins Leukot Essent Fatty Acids, Oct-Nov; 75(4-5):299-308, 2006 (Epub 2006 Sept 8; refer to PubMed ID # 16962757)
Auestad, N., et al, Visual, cognitive, and language assessment at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age, Pediatrics, Sept; 112(1Pt 1):e177-e183, 2003
De Vizia, B., et al, Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic ) in patients with cystic fibrosis, J Parenter Enteral Nutr, Jan-Feb; 27(1):52-57, 2003
Horrocks, L.A., Yeo, Y.K., Health benefits of docosahexaenoic acid (DHA), Pharmacol Res, Sept; 40(3):211-225, 1999
L. Hodge, C.M. Salome, et al, Consumption of oily fish and childhood asthma risk, Medical Journal of Australia, 164:137-140, 1996
Lee, T.H., Hoover, R.L., Williams, J.D., et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function, N Engl J Med. 312:1217-1224, 1985
McNamara, R.K., Carison, S.E., Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology, Prostaglandins Leukot Essent Fatty Acids, Oct-Nov; 75(4-5):329-349, 2006 (Epub 2006 Sept 1; refer to PubMed ID # 16949263)
Nagakura, T., et al, Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma, Eur Respir J, Nov, 16(5):861-5, 2000
Richardson, A.J., Omega-3 fatty acids in ADHD and related neurodevelopmental disorders, Int Rev Psychiatry, April; 18(2):155-172, 2006
Singh, M., Essential fatty acids, DHA and human brain, Indian J Pediatr, Mar; 72(3):239-242, 2005
Sliwinski, S., et al, Poly Unsaturated fatty acids: Do they have a role in the pathophysiology of autism?, Neuro Endocrinol Lett, Aug 5; 27(4), 2006 Epub ahead of print. Refer to PubMed ID No.16891996
Thies, N.H., The effect of 12 months treatment with eicosapentaenoic acid in five children with cystic fibrosis, J Paediatr Child Health, Aug; 33(4):349-351, 1997
This information is for educational purposes only and is not intended to diagnose or cure.
